Efinaconazole in the treatment of onychomycosis
Shari R Lipner, Richard K Scher Department of Dermatology, Weill Cornell Medical College, New York, NY, USA Abstract: Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-06-01
|
| Series: | Infection and Drug Resistance |
| Online Access: | http://www.dovepress.com/efinaconazole-in-the-treatment-of-onychomycosis-peer-reviewed-article-IDR |
| id |
doaj-abf6f8e813f042858c843a21afd2d33a |
|---|---|
| record_format |
Article |
| spelling |
doaj-abf6f8e813f042858c843a21afd2d33a2020-11-24T21:09:46ZengDove Medical PressInfection and Drug Resistance1178-69732015-06-012015default16317221958Efinaconazole in the treatment of onychomycosisLipner SRScher RKShari R Lipner, Richard K Scher Department of Dermatology, Weill Cornell Medical College, New York, NY, USA Abstract: Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol biosynthesis pathway, has potent antifungal activity against dermatophytes, as well as activity against Candida spp. and non-dermatophyte molds, and showed promising results in clinical trials. This review summarizes the mechanism of action, in vitro and in vivo data, clinical trials, safety, and quality-of-life data of efinaconazole as it applies to the treatment of onychomycosis. Keywords: efinaconazole, Jublia, onychomycosis, fungal infection, nail infection http://www.dovepress.com/efinaconazole-in-the-treatment-of-onychomycosis-peer-reviewed-article-IDR |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Lipner SR Scher RK |
| spellingShingle |
Lipner SR Scher RK Efinaconazole in the treatment of onychomycosis Infection and Drug Resistance |
| author_facet |
Lipner SR Scher RK |
| author_sort |
Lipner SR |
| title |
Efinaconazole in the treatment of onychomycosis |
| title_short |
Efinaconazole in the treatment of onychomycosis |
| title_full |
Efinaconazole in the treatment of onychomycosis |
| title_fullStr |
Efinaconazole in the treatment of onychomycosis |
| title_full_unstemmed |
Efinaconazole in the treatment of onychomycosis |
| title_sort |
efinaconazole in the treatment of onychomycosis |
| publisher |
Dove Medical Press |
| series |
Infection and Drug Resistance |
| issn |
1178-6973 |
| publishDate |
2015-06-01 |
| description |
Shari R Lipner, Richard K Scher Department of Dermatology, Weill Cornell Medical College, New York, NY, USA Abstract: Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol biosynthesis pathway, has potent antifungal activity against dermatophytes, as well as activity against Candida spp. and non-dermatophyte molds, and showed promising results in clinical trials. This review summarizes the mechanism of action, in vitro and in vivo data, clinical trials, safety, and quality-of-life data of efinaconazole as it applies to the treatment of onychomycosis. Keywords: efinaconazole, Jublia, onychomycosis, fungal infection, nail infection |
| url |
http://www.dovepress.com/efinaconazole-in-the-treatment-of-onychomycosis-peer-reviewed-article-IDR |
| work_keys_str_mv |
AT lipnersr efinaconazoleinthetreatmentofonychomycosis AT scherrk efinaconazoleinthetreatmentofonychomycosis |
| _version_ |
1716757418492297216 |